Satralizumab-mwge
Satralizumab-mwge
Satralizumab-mwge (pronunciation: sa-tra-li-zu-mab-mwge) is a monoclonal antibody medication used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody. It is sold under the brand name Enspryng.
Etymology
The name Satralizumab-mwge is derived from the International Nonproprietary Names (INN), where 'satra' is a stem used for humanized antibodies, 'lizu' indicates interleukin 6 (IL-6) immunomodulation, 'mab' is a common suffix for monoclonal antibodies, and 'mwge' is a suffix used to denote a monoclonal antibody subunit.
Mechanism of Action
Satralizumab-mwge works by binding to the interleukin 6 (IL-6) receptor and blocking the signal transduction of IL-6, a cytokine that plays a key role in the inflammatory process in NMOSD.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Neuromyelitis Optica Spectrum Disorder (NMOSD): A chronic disorder of the brain and spinal cord that includes inflammation of the optic nerve and inflammation of the spinal cord.
- Interleukin 6 (IL-6): A type of cytokine that is involved in inflammation and in the maturation of B cells.
- Cytokine: A type of protein that is secreted by immune cells and acts to regulate an immune response.
- Signal Transduction: The process by which a chemical or physical signal is transmitted through a cell as a series of molecular events.
External links
- Medical encyclopedia article on Satralizumab-mwge
- Wikipedia's article - Satralizumab-mwge
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski